157P Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of first-line systemic chemotherapy

Y Cheng,L Shen,X Yu,Z Chen,L Song,Y Zhang,C Wu,M Lu,H Gao,W Chen,M Yang,Y Ma,J Zhou,H Shi,P Tan,S Fan,W Su

doi:10.1016/j.annonc.2021.10.176

157P Surufatinib plus toripalimab in patients with advanced small cell lung cancer (SCLC) after failure of first-line systemic chemotherapy

Y Cheng, L Shen + Show 15 more

Open Access

https://doi.org/10.1016/j.annonc.2021.10.176

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Jilin Province Tumor Hospital, Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, Second Hospital of Anhui Medical University, First Affiliated Hospital of Zhengzhou University, Third Affiliated Hospital of Harbin Medical University, Hua Medicine (China)

#Small Cell Lung Cancer Cohort #Small Cell Lung Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Patients (pts) with advanced SCLC have a rapid relapse after 1L treatment, and only one approved agent (topotecan) for 2L treatment. Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) has exhibited encouraging efficacy in a neuroendocrine carcinoma cohort in a trial evaluating S + T in pts with selected solid tumors. Here, we report the safety and efficacy results in the SCLC cohort.

Full Text